Skip to Main Content

Advertisement

Current Issue
Volume 134,
Issue 19,
November 7, 2019

Issue Highlights

Featured Content


Serpin targets in hemostasis/kinin formation

Targeting natural anticoagulant proteins as a means to rebalance the hemostatic system is an emerging trend in the development of innovative therapeutic strategies for hemophilia.


Chromatin occupancy and epigenetic analysis reveal new insights into the function of the GATA1N terminus in erythropoiesis

GATA1 has a foundational role in erythropoiesis. The investigators compare the function of 2 forms (the full-length protein and a shorter form) of the transcription factor GATA1 and show that the N-terminal domain of GATA1 is critical to red cell differentiation.


Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma

In this Blood Spotlight, the authors review the appropriate clinical background, mechanism of action, and detailed therapeutic data about duvelisib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma.


The whole-genome landscape of Burkitt lymphoma subtypes

Burkitt lymphoma (BL) is an aggressive, MYC-driven lymphoma comprising 3 distinct clinical subtypes: sporadic BLs that occur worldwide, endemic BLs that occur predominantly in sub-Saharan Africa, and immunodeficiency-associated BLs that occur primarily in the setting of HIV.


New approaches to molecular monitoring in CML (and other diseases)

This study reveals that successful therapeutic targeting of the CD47-SIRPa axis in peripheral T-cell lymphoma is highly dependent on the Fc-FcgR interaction and is augmented by cotreatment with the anti-CCR4–targeted monoclonal antibody mogamulizumab.


Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD

These studies demonstrate how activation of the NLRP3 inflammasome pathway influences the function of myeloid-derived suppressor cells (MDSCs) in the setting of acute graft-versus-host disease (aGVHD)..

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement